ABAXIS, Inc. (ABAX): M&A News

ABAX – Abaxis to be acquired by Zoetis for $83 per share in cash, or approximately $2.0 billion.

Key Facts Surrounding This News Item

  • ABAX had a POWR Rating of B (Buy) coming into today.
  • ABAX was 3.48% above its 10-Day Moving Average coming into today.
  • ABAX was 2.35% above its 20-Day Moving Average coming into today.
  • ABAX was 0.87% above its 50-Day Moving Average coming into today.
  • ABAX was 7.22% above its 100-Day Moving Average coming into today.
  • ABAX was 26.25% above its 200-Day Moving Average coming into today.
  • ABAX had returned +44.89% year-to-date leading up to today’s news, versus a +2.00% return from the benchmark S&P 500 during the same period.

More Info About ABAXIS, Inc. (ABAX)

Abaxis is a developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. The company was founded in 1989 and is based in Union City, California. View our full ABAX ticker page with ratings, news, and more.

ABAX at a Glance

ABAX Current POWR Rating™
Overall POWR Rating™
ABAX Current Price $83.00 0.11%
More ABAX Ratings, Data, and News

ABAX Price Reaction

The day of this event (May. 16, 2018)
ABAX Closing Price$83.34 16.15%
ABAX Volume4,300,300
2,939.62% from avg
Leading up to this event
ABAX 1-mo return2.75%
After this event
ABAX 1-day return14.30%
ABAX 3-day return13.55%
ABAX 5-day return13.56%

ABAX Price Chart

The Top Stocks For 2019

More ABAXIS, Inc. (ABAX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ABAX News
Page generated in 1.0744 seconds.